At both dose levels, NTLA-2002 was well tolerated. The most frequent adverse events (AEs) were headache, fatigue and nasopharyngitis. There have been no serious AEs and all AEs were either Grade 1 ...

Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary angioedema ...

Strategic focus on developing NTLA-2002 and nex-z, which are expected to create significant near-term value, highlighting the company’s commitment to addressing unmet medical needs in hereditary ...

1 Investigator confirmed HAE attack rate. 2 On-study period is defined as the time from the dosing of NTLA-2002 through the last assessment of HAE attacks as of the data cut-off date. Across all ...

NTLA-2002 has the potential to be the first one-time CRISPR-based treatment for hereditary angioedema, presenting a new treatment paradigm for this condition.

Positive results for Intellia Therapeutics, Inc.'s NTLA-2002 in treating HAE patients. Stock price dips, but the program continues. Click for my NTLA update.

Investing.com -- Shares of Intellia Therapeutics (NASDAQ:NTLA), Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its investigational ...

NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity. In the past year, shares of Intellia have plunged 56.1% compared with the industry’s decline of 12%.

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate ...

CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single ...